Shengye Lu

Beijing Key Laboratory Of Hematopoietic Stem Cell Transplantation
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs.

Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs.

Journal: Cell transplantation

Published: December 16, 2025

DynaMamba: Multi-scale dynamic interacting Mamba network for irregular clinical time series classification.

DynaMamba: Multi-scale dynamic interacting Mamba network for irregular clinical time series classification.

Journal: Journal of biomedical informatics

Published: November 27, 2025

Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation.

Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation.

Journal: Journal of translational internal medicine

Published: September 02, 2025

A temporal deep learning algorithm for prediction of extubation failures in critical care patients.

A temporal deep learning algorithm for prediction of extubation failures in critical care patients.

Journal: Journal of clinical monitoring and computing

Published: August 30, 2025

DEK-NUP214 monitoring before and after allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia: A report from the TROPHY study group.

DEK-NUP214 monitoring before and after allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia: A report from the TROPHY study group.

Journal: Journal of translational internal medicine

Published: August 27, 2025

Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Elderly Patients With Acute Leukemia Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.

Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Elderly Patients With Acute Leukemia Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.

Journal: Clinical transplantation

Published: March 27, 2025

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.

Journal: Annals of hematology

Published: August 05, 2024

Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.

Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.

Journal: Annals of hematology

Published: November 25, 2023

TSOANet: Time-Sensitive Orthogonal Attention Network for medical event prediction.

TSOANet: Time-Sensitive Orthogonal Attention Network for medical event prediction.

Journal: Artificial intelligence in medicine

Published: July 30, 2023

Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.

Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.

Journal: Annals of hematology

Published: July 28, 2023

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study.

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study.

Journal: Leukemia research reports

Published: May 14, 2022

Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.

Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.

Journal: British journal of haematology

Published: November 23, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026